For decades, naked mole rats have captivated scientists due to their extraordinary longevity and apparent immunity to cancer, prompting speculation that their cells harbor unique anti-cancer mechanisms. This remarkable resilience has positioned them as a natural model organism for uncovering the molecular underpinnings of tumor suppression. Using cutting-edge CRISPR-Cas9 gene-editing technology, the Moffitt research team introduced a specific oncogenic genetic alteration—known as the EML4-ALK fusion gene—into naked mole rat cells. This genetic fusion, well-documented as a potent driver of lung cancer in humans and murine models, initiates unchecked cellular proliferation and tumor formation in those species.

Contrary to expectations, the introduction of the EML4-ALK fusion alone did not induce lung tumors in the naked mole rats, indicating an inherent resilience to this oncogenic signal. Subsequent experiments revealed that tumorigenesis required additional genetic hits—in particular, the simultaneous loss of two critical tumor suppressor genes, p53 and Rb1. These genes are pivotal guardians of genomic integrity, executing cellular programs that prevent malignancy by initiating DNA repair, cell cycle arrest, or apoptosis in response to oncogenic stress. Only upon the combined presence of EML4-ALK and the inactivation of p53 and Rb1 did roughly 30% of the naked mole rats develop aggressive lung tumors.

Remarkably, these induced tumors paralleled a rare but clinically significant subtype of human lung cancer known as pleomorphic carcinoma. Characterized by diverse cellular morphology and aggressive behavior, pleomorphic carcinoma is often refractory to current targeted therapies. The morphological and molecular fidelity of tumors in naked mole rats thus establishes this model as an invaluable platform for probing disease mechanisms and testing novel interventions, potentially bridging gaps between preclinical studies and patient outcomes.

Dr. Joseph Kissil, senior author of the study and chair of Moffitt’s Molecular Oncology Department, highlighted the significance of the findings: “Our work demonstrates that naked mole rats, like humans, require multiple genetic alterations to overcome intrinsic tumor suppression and initiate malignancy. This insight underscores their value as a more genetically faithful model for studying early cancer events compared to traditional murine models.” By reflecting the multifactorial nature of human tumorigenesis, naked mole rats may enable scientists to dissect complex oncogenic interactions with unprecedented precision.

Another compelling aspect of this research lies in the characterization of the tumor microenvironment within naked mole rats. The researchers documented a heterogeneous infiltrate of immune cells, including T lymphocytes and macrophages, within the tumors—elements known to influence cancer progression and response to therapy. The presence of active immune components mirrors human tumor biology more accurately than many existing animal models, suggesting that naked mole rats can also serve as a unique system for immuno-oncology studies. Understanding how cancer interacts with the immune system in this species may unlock insights into immune surveillance mechanisms that contribute to their natural cancer resistance.

Despite the logistical challenges associated with breeding and maintaining naked mole rats in laboratory settings—given their specialized social structures and environmental needs—the research team advocates for the broader adoption of these animals as a robust cancer research model. Unlike mice, whose tumorigenic processes often rely on singular oncogenic drivers, naked mole rats embody the complexity and multiplicity of genetic events required for malignant transformation in humans, thereby offering a more clinically relevant investigative tool.

The development of this model was a painstaking, years-long process that involved the creation of specialized molecular tools and the optimization of gene delivery systems tuned to the naked mole rat’s unique biology. This foundational work establishes a comprehensive platform from which future studies can systematically unravel the earliest stages of lung cancer initiation, monitor tumor evolution, and evaluate the efficacy of therapeutic agents tailored to intricate oncogenic pathways.

Moreover, this platform is poised to shine light on pleomorphic lung carcinoma, a cancer subtype that remains poorly understood and lacks effective targeted treatments. By recapitulating the cellular and molecular landscape of this disease in a genetically defined animal model, researchers can conduct mechanistic analyses and high-throughput drug screening with greater translational applicability.

The implications of this study extend beyond lung cancer. Unraveling how naked mole rats resist tumorigenesis until multiple stringent genetic alterations coalesce may illuminate generalizable principles of cancer prevention inherent in biology. These insights could translate into innovative strategies for enhancing tumor suppression or circumventing resistance mechanisms in human patients.

Finally, this research underscores the critical importance of integrating comparative biology with cutting-edge genetic engineering to develop advanced disease models. The naked mole rat’s unique evolutionary adaptations present a natural experiment in cancer biology; leveraging these adaptations with precise molecular tools heralds a new era in oncology research that transcends conventional paradigms.

As the scientific community seeks effective therapies for elusive and aggressive cancers, the advent of the naked mole rat lung cancer model offers a beacon of hope. Through meticulous and rigorous study of this novel system, researchers aspire to unlock therapeutic strategies not only to combat lung cancer but also to redefine cancer prevention and treatment paradigms at large.

Subject of Research: Animals

Article Title: An Autochthonous Model of Lung Cancer Identifies Requirements for Cellular Transformation in the Naked Mole-Rat

News Publication Date: 8-Sep-2025

Web References:

• Moffitt Cancer Center
• Lung Cancer Information
• Cancer Discovery Article

References:
Kissil, J. et al. (2025). An Autochthonous Model of Lung Cancer Identifies Requirements for Cellular Transformation in the Naked Mole-Rat. Cancer Discovery. DOI: 10.1158/2159-8290.CD-25-0526.

Keywords: Cancer research

Central to this advancement is the tool’s unprecedented capacity to rapidly profile tRNA modifications using a fully automated pipeline, integrating robotic liquid handling with high-precision liquid chromatography-tandem mass spectrometry (LC-MS/MS). This combination notably reduces the manual effort, cost, and hazardous chemical exposure that have long hindered scalable studies of RNA modifications. The implications are far-reaching: by unlocking the hidden regulatory networks encoded in RNA chemical marks, researchers are now empowered to decode complex cellular adaptations in diseases such as cancer and antibiotic-resistant infections.

Chemical modifications on tRNAs, which serve as molecular adaptors in protein synthesis, fine-tune cellular responses to a myriad of physiological challenges, including oxidative stress, nutrient scarcity, and microbial invasion. Until now, profiling these modifications system-wide at high throughput remained a formidable challenge due to inherently labor-intensive protocols and technical limitations. The SMART-developed platform overcomes these obstacles by automating sample preparation and data acquisition for tens of thousands of samples, facilitating a scale of investigation previously unattainable.

Demonstrating the capabilities of their system, researchers applied it to over 5,700 genetically modified strains of Pseudomonas aeruginosa, a notorious pathogen responsible for a variety of infections including pneumonia and sepsis. The automated analysis generated more than 200,000 high-resolution data points, revealing novel RNA-modifying enzymes and detailed mapping of epitranscriptomic regulatory networks. Such insights illuminate how bacterial cells navigate hostile environments, adapt metabolically, and resist antibiotics—processes central to infection persistence and treatment failure.

A standout discovery enabled by this platform involves the methylthiotransferase MiaB, an enzyme critical for the tRNA modification ms2i6A. The data indicated that MiaB activity is intricately modulated by intracellular iron and sulfur availability, and oxygen tension, reflecting a sophisticated mechanism by which bacteria sense and respond to microenvironmental changes. This nuanced understanding could catalyze the identification of new antimicrobial targets and lead to therapies that subvert bacterial survival strategies.

Beyond infectious disease, this technology holds transformative potential for cancer research. RNA modifications are increasingly recognized as pivotal regulators of oncogenic pathways, influencing tumor growth, metastasis, and response to therapy. By enabling rapid, expansive epitranscriptome profiling, the SMART tool equips scientists with a powerful means to discover biomarkers for early detection, prognosis, and therapeutic stratification in oncology.

The methodological innovation lies not only in throughput but in the safety and reproducibility gains achieved. Traditional tRNA modification analyses frequently rely on toxic solvents like phenol and chloroform, posing health risks and variability in results. The SMART platform’s integrated robotics automate enzymatic digestion and sample processing steps, obviating manual handling of hazardous compounds, thus setting a new standard for laboratory safety and experimental consistency.

This comprehensive, system-wide approach provides a holistic snapshot of the epitranscriptome, a level of insight that surpasses targeted analyses traditionally employed. By capturing quantitative profiles of multiple tRNA modifications concurrently, the technology reveals interconnected regulatory circuits and post-transcriptional modifications that govern gene expression dynamics under normal and pathological states.

The implications extend into pharmaceutical and biotechnological realms, where this tool offers a strategic advantage for drug development and screening. Pharmaceutical companies can deploy high-throughput RNA modification profiling to evaluate candidate drugs’ effects on epitranscriptomic landscapes, accelerating biomarker discovery and optimizing therapeutic efficacy with greater precision.

As co-lead Principal Investigator Prof. Peter Dedon emphasized, this innovation transforms how researchers decode RNA’s regulatory language, with the potential to unravel complex gene networks involved in cancer progression and antimicrobial resistance. Such knowledge is critical for designing next-generation diagnostics and interventions tailored to patient-specific molecular profiles, embodying the promise of personalized medicine.

Looking ahead, the SMART AMR team envisions extending the platform’s application beyond microbial models to human cells and tissues. By interrogating human epitranscriptomes at scale, researchers can deepen understanding of disease mechanisms, identify novel clinical biomarkers, and propel development of customized treatment regimens. This transfer from bench to bedside signifies a crucial step in translating epitranscriptomic research into tangible healthcare solutions.

Supported by the National Research Foundation Singapore’s CREATE program, this development exemplifies successful interdisciplinary collaboration, uniting expertise from bioengineering, molecular biology, mass spectrometry, and computational analytics. The confluence of these fields has culminated in a tool that responds to pressing global health challenges by accelerating discovery and translational research in RNA biology.

In sum, the SMART-developed automated tRNA modification profiling system is a landmark technological advancement that paves the way for high-throughput epitranscriptomic studies. Its ability to rapidly and safely assay RNA chemical modifications at scale promises to revolutionize fundamental biological research, expedite drug discovery pipelines, and usher in a new paradigm of precision medicine targeting RNA regulatory mechanisms in cancer and infectious diseases.

Subject of Research: Cells

Article Title: tRNA modification profiling reveals epitranscriptome regulatory networks in Pseudomonas aeruginosa

News Publication Date: 3 September 2025

Web References:
https://smart.mit.edu/research/amr/about-amr
https://smart.mit.edu/
https://academic.oup.com/nar/article/53/14/gkaf696/8213826

References:
Dedon, P., Sun, J. et al. (2025). tRNA modification profiling reveals epitranscriptome regulatory networks in Pseudomonas aeruginosa. Nucleic Acids Research, 53(14). DOI: 10.1093/nar/gkaf696

Image Credits: SMART AMR

Keywords: Biomedical engineering, Cancer cells, Cells, Cancer, RNA, Transfer RNA

Colorectal cancer, a formidable health challenge worldwide, has long been recognized as a heterogeneous disease. Yet, the nuances that distinguish tumors based on their anatomical origin within the colon have remained elusive. This study dives deep into the molecular fabric that underpins these differences, offering a nuanced perspective that transcends traditional pathological classifications. The researchers utilized advanced gene expression analyses to compare the levels of CMTM3 and SSTR2 in tumor samples sourced from distinct colon segments—right and left. Their findings suggest that these genes may not just be passive markers but active players influencing tumor behavior and progression.

CMTM3 (CKLF-like MARVEL transmembrane domain-containing 3) emerges in this narrative as a gene with profound implications. Known to be involved in immune regulation and tumor suppression, CMTM3’s variation in expression between colon tumor locations could signal divergent tumor microenvironments and immune evasion strategies. The study reveals that alterations in CMTM3 expression are more prominent in right-sided colon tumors, raising compelling questions about how this gene modulates carcinogenesis on a molecular level within this specific colon region.

SSTR2 (somatostatin receptor 2), another gene meticulously examined, encodes a receptor integral to regulating hormone secretion and cellular proliferation. Its expression patterns in colorectal tumors have been linked to varying responses to somatostatin analogues, compounds used in certain cancer therapies. The study reports a differential expression of SSTR2 in left-sided tumors compared to those on the right, suggesting that tumor location could influence responsiveness to receptor-targeted therapies. This discovery opens avenues to rethink therapeutic approaches, potentially tailoring them based on tumor localization.

The methodology underpinning the research reflects the rigor of contemporary molecular oncology. Tumor specimens underwent quantitative gene expression profiling using state-of-the-art molecular techniques, enabling precise measurement of mRNA levels for CMTM3 and SSTR2. These data were then meticulously correlated with clinicopathologic features, allowing the researchers to draw robust conclusions about the biological implications of their findings. The comprehensive nature of the dataset lends credibility to the notion that colorectal tumors cannot be universally characterized but must be dissected according to their anatomical and molecular idiosyncrasies.

One of the pivotal insights derived concerns the embryological and biological distinctions of the colon itself. The right and left sections derive from different embryonic origins—the midgut and hindgut, respectively—and this divergence is reflected in gene expression patterns and tumor characteristics. The study’s results support the hypothesis that such developmental origins have lasting effects on the molecular constitution of ensuing neoplasms. This emphasizes the necessity to incorporate anatomical context when considering prognostic markers and treatment regimens for CRC.

The differential gene expression of CMTM3 and SSTR2 might also intertwine with the immune landscape of colorectal tumors. Given CMTM3’s role in immune modulation, its elevated expression in right-sided tumors may contribute to a distinct immune microenvironment that affects tumor progression and patient outcomes. Similarly, varying SSTR2 levels could impact how the tumor interfaces with neuroendocrine signaling pathways, modulating growth signals in localized contexts. Together, these shifts highlight a sophisticated, location-specific interplay between genetics and tumor ecology.

From a clinical standpoint, these revelations could have transformative implications. Right-sided colon cancers are notorious for their poorer prognosis and reduced response rates to standard chemotherapy compared to left-sided cancers. Understanding the genetic underpinnings responsible for this disparity provides a molecular framework to develop location-specific biomarkers that predict therapy response with higher accuracy. This may drive a paradigm shift from a one-size-fits-all approach to precision oncology in colorectal cancer treatment.

Furthermore, the study lays foundational knowledge for exploiting these gene expression differences therapeutically. Targeting SSTR2, for instance, could be innovated upon to develop receptor-specific drugs for left-sided tumors, while reactivating or mimicking CMTM3 function might arrest right-sided tumor progression. These possibilities underscore the burgeoning field of gene-directed therapy in oncology, where genetic signatures not only diagnose but also direct treatment and monitor disease trajectory.

The significance of this study extends beyond the immediate findings to challenge prevailing clinical practice. Traditionally, CRC has been treated as a single entity, with little regard for tumor location. This research compellingly argues that the colon’s molecular ecology dictates a need for reclassification of colorectal cancer subtypes. It calls for comprehensive molecular profiling as part of routine diagnostic workflows, ensuring that treatment plans resonate with the tumor’s unique genetic identity.

Moreover, the interplay between tumor genetics and patient lifestyle or environmental factors could also be influenced by tumor location, an angle ripe for exploration. Diet, microbiota composition, and exposure to carcinogens differ along the colon, possibly driving the divergent expression patterns observed. Integrating molecular genetics with epidemiological data could further refine risk stratification and preventive strategies in colorectal cancer.

The authors advocate for expanded studies that encompass larger, multi-center cohorts, employing integrative genomic, transcriptomic, and proteomic analyses. Such holistic approaches would further clarify the complex molecular crosstalk within colonic tumors. They also emphasize the importance of longitudinal studies to understand how these gene expression disparities evolve during tumorigenesis and impact clinical outcomes over time.

Finally, this research highlights the vital role of translational science bridging the gap between bench and bedside. By decoding the molecular discrepancies of right and left colon tumors, scientists and clinicians are better equipped to innovate diagnostic, prognostic, and therapeutic tools tailored to individual cancers. As precision medicine continues to evolve, studies like these will be instrumental in transforming colorectal cancer from a monolithic disease into a spectrum of distinct, targetable entities.

In conclusion, the revelation of differential expression of CMTM3 and SSTR2 genes in right versus left colon tumors represents a significant advance in the molecular pathology of colorectal cancer. This study not only demystifies the biological heterogeneity underpinning CRC but also ignites hope for more nuanced, effective, and personalized interventions that could ultimately enhance survival and quality of life for millions affected globally.

Subject of Research: Molecular differences in gene expression (CMTM3 and SSTR2) between right and left colon tumors in colorectal cancer.

Article Title: Differences in the expression of CMTM3 and SSTR2 genes in right and left colon tumors: A molecular insight into colorectal cancer.

Article References:
Binen, T., Akbaş, E., Çolak, T., et al. Differences in the expression of CMTM3 and SSTR2 genes in right and left colon tumors: A molecular insight into colorectal cancer. Med Oncol 42, 382 (2025). https://doi.org/10.1007/s12032-025-02961-5

Image Credits: AI Generated